Nuvation Bio (NUVB) is back in focus after the UK Medicines and Healthcare products Regulatory Agency validated a Marketing Authorisation Application for taletrectinib in advanced ROS1-positive non small cell lung cancer.
See our latest analysis for Nuvation Bio.
The latest MHRA validation comes as Nuvation Bio’s share price trades at US$5.81, with a 1 month share price return of 18.1% and a 90 day share price return of 19.8%. Year to date the share price is down 32.3%, while the 1 year total shareholder return is 171.5% and the 3 year total shareholder return is about 2.4x, suggesting momentum has picked up recently after a weaker start to the year.
If regulatory milestones like this have your attention, it could be a good moment to see what else is developing in healthcare related AI, starting with our 40 healthcare AI stocks
Nuvation Bio now has a marketed lung cancer therapy and fresh regulatory momentum, but after a sharp rebound in the share price, is the stock still offering solid value, or has the recent excitement already been priced in?
Most Popular Narrative: 52.9% Undervalued
Nuvation Bio's most followed narrative points to a fair value of $12.33 against a last close of $5.81. The story centers on whether the current price reflects those long term assumptions.
Analysts are assuming Nuvation Bio's revenue will grow by 46.0% annually over the next 3 years.
Analysts are not forecasting that Nuvation Bio will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Nuvation Bio's profit margin will increase from -102.1% to the average US Pharmaceuticals industry of 19.4% in 3 years.
Interested in how a still loss making Nuvation Bio ends up with that kind of valuation gap? The fair value hinges on rapid revenue expansion, a major swing in margins and a future earnings multiple that assumes investors keep paying up for that growth profile.
Result: Fair Value of $12.33 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Nuvation Bio narrative could be challenged if IBTROZI faces tougher competition than expected, or if safusidenib timelines slip further and delay that second revenue pillar.
Find out about the key risks to this Nuvation Bio narrative.
Another View: Nuvation Bio Through the Sales Multiple Lens
The fair value narrative for Nuvation Bio points to a large upside gap, yet the P/S ratio tells a more cautious story. At about 14.1x sales versus a US Pharmaceuticals industry average of 6.2x and a fair ratio of 14.8x, the stock screens expensive against peers but roughly in line with where the model suggests the multiple could settle. This raises the question of whether this reflects justified growth expectations or a thinner margin for error at today’s price.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With mixed signals around value and risk at Nuvation Bio, now is a good time to review the underlying numbers and sentiment for yourself, then weigh up the balance of potential upsides and downsides with the help of the 2 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Nuvation Bio?
If Nuvation Bio has caught your attention, do not stop there. Use screening tools to find other opportunities that might suit your style and risk tolerance.
- Target potential mispricings by scanning a curated list of quality stocks trading below their estimated worth with the 45 high quality undervalued stocks.
- Prioritize resilience by focusing on companies that pair lower risk profiles with durable fundamentals through the 79 resilient stocks with low risk scores.
- Spot under followed opportunities early by browsing a screener containing 19 high quality undiscovered gems before they appear on everyone else's radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com